As a full agonist at equally the CB1 and CB2 cannabinoid receptors, this chemical compound is assessed as an analgesic medication. The analgesic results of cannabinoid ligands, mediated by CB1 receptors are well recognized in treatment of neuropathic pain, and most cancers ache and arthritis.The likelihood that SCs use could result in liver damage